• Erectile Dysfunction Guideline Update Panel. AUA guideline on the pharmacologic management of premature ejaculation. Linthicum (MD): American Urological Association, Inc.; 2004. 19 p. [30 references]

This is the current release of the guideline.

Note from the National Guideline Clearinghouse: The recommendations without the associated supporting text have been excerpted from the guideline. For full context, please refer to the original guideline document.

Recommendation 1:

The diagnosis of premature ejaculation (PE) is based on sexual history alone. A detailed sexual history should be obtained from all patients with ejaculatory complaints. (Based on Panel consensus.)

Recommendation 2:

In patients with concomitant PE and erectile dysfunction (ED), the ED should be treated first. (Based on Panel consensus.)

Recommendation 3:

The risks and benefits of all treatment options should be discussed with the patient prior to any intervention. Patient and partner satisfaction is the primary target outcome for the treatment of PE. (Based on Panel consensus.)

Recommendation 4:

Premature ejaculation can be treated effectively with several serotonin reuptake inhibitors (SRIs) or with topical anesthetics. The optimal treatment choice should be based on both physician judgment and patient preference. (Based on Panel consensus and review of data.)

None provided

The type of supporting evidence is not specifically stated for each recommendation. The majority of the recommendations contained in the guideline are based on a consensus of expert opinion following review of the literature. In some cases, expert consensus is supplemented with a focused review of the limited data.

• Erectile Dysfunction Guideline Update Panel. AUA guideline on the pharmacologic management of premature ejaculation. Linthicum (MD): American Urological Association, Inc.; 2004. 19 p. [30 references]

Not applicable: The guideline was not adapted from another source.

2004

American Urological Association Education and Research, Inc. - Medical Specialty Society

American Urological Association, Inc. (AUA)

Erectile Dysfunction Guideline Update Panel

Panel Members: Drogo K. Montague, MD, Cochair; Jonathan Jarow, MD, Cochair; Gregory A. Broderick, MD; Roger R. Dmochowski, MD; Jeremy P.W. Heaton, MD; Tom F. Lue, MD; Ajay Nehra, MD; Ira D. Sharlip, MD

Consultants: Hanan S. Bell, PhD; Patrick M. Florer; Diann Glickman, PharmD

Not stated

This is the current release of the guideline.

None available

This NGC summary was completed by ECRI on June 10, 2004. The information was verified by the guideline developer on August 4, 2004. This summary was updated by ECRI on May 31, 2006 following the U.S. Food and Drug Administration advisory on Paxil (paroxetine hydrochloride). This summary was updated by ECRI Institute on November 6, 2007, following the U.S. Food and Drug Administration advisory on Antidepressant drugs.

This NGC summary is based on the original guideline, which is copyrighted by the American Urological Association, Inc. (AUA).